NEWS & COMMENTS

PROHOST    FILTER

ONLY IMPORTANT

                      DENDREON: PROMISING RESULTS OF ATHERAPEUTIC VACCINE

DENDREON (DNDN): Results of pivotal Phase 3 study (D9901) of Provenge® (sipuleucel-T) as they appeared in the July issue of the Journal of Clinical Oncology are promising. Investors seem to appreciate these results.  The journal article highlights the significant survival benefit and favorable safety profile of Provenge, the company's investigational active cellular immunotherapy, in men with advanced androgen-independent prostate cancer. Dendreon decided to submit a Biologics License Application (BLA) to the FDA later this year to obtain approval to market Provenge. Good news, indeed, and the drug could become the first in its category, i.e therapeutic vaccines, to be approved for the treatment of cancer. This is the second good news in a few weeks about vaccines preventing and treating diseases. The first was the approval of a vaccine developed by Merck, which resorted to MedImmune’s technology, for the prevention of cervical cancer caused by human papillomavirus. If approved, Dendreon's prostate cancer vaccine will be a historical precedent.

READ MORE:  Dendreon Announces Publication of Pivotal Phase 3 Study Highlighting Survival Benefit and Safety Profile of PROVENGE in Men With Advanced Prostate Cancer   

                                          GENENTECH: APPROVAL OF LUCENTIS

GENENTECH (DNA): The FDA approved Lucentis™ (ranibizumab injection) for neovascular (wet) age-related macular degeneration (AMD) after a Priority Review (six-month). Genentech will ship product right away.

Nearly all patients (95 percent) treated with Lucentis maintained their vision in the Phase 3 clinical trials. Vision improved by at least three lines (or 15 letters) on the study eye chart in up to 40 percent of these patients at one year. The drug inhibits the formation and leakage of new blood vessels in the back of the eye, the primary cause of central vision loss associated with wet age-related macular degeneration.

READ MORE:  FDA Approves LUCENTIS for the Treatment of Wet Age-Related Macular Degeneration

Prohost is independent publication providing information on biotech companies. Prohost does not accept compensation from companies that are featured or profiled. It is strongly recommended that any purchase or sale decisions to any of the featured companies be discussed with a financial advisor or broker prior to completing any such purchase or sale decision. All statements or expressions are the opinion of Prohost and are not meant to be a solicitation or recommendation to buy, sell, or hold securities. Investing in embryonic companies, micro-cap and growth securities is highly speculative and carries a high degree of risk. It is possible that an investor can lose all of his/her investment in this type of companies that are profiled. The information that Prohost relies on is either through the profiled company, news services, research reports, interviews, or other outside sources that Prohost believes are reliable. Prohost makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure of the profiled companies and accepts no responsibilities for inaccuracies or misleading content in any material supplied by those clients. There can be no assurance that future events relating to the profiled company will occur as anticipated. The information contained herein is provided as an information service only. Past performance of featured companies does not guarantee the future success of any currently featured or profiled company. We encourage our readers to invest carefully and read the investor information provided by the Securities and Exchange Commission ("SEC") and/or the National Association of Securities Dealers ("NASD"). We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at: http://www.sec.gov/consumer/cyberfr.htm